Okay y’all… I’ve been digging into Editas Medicine $EDIT and low-key this might be the most underrated player in the whole CRISPR game. While everyone’s busy drooling over the big names, $EDIT is out here pivoting into full in-vivo gene editing like they’re trying to speedrun the future. Their new LNP delivery tech + gene-upregulation strategy is actually wild if they pull it off, imagine editing cells inside the body without all that complicated lab drama.

Yeah the stock’s cheap, yeah it’s risky, but the upside?? Kinda insane if their sickle-cell program hits.

So be honest…. are we loading up early or letting this one slide?